

MORE THAN JUST SURVIVAL



HALAVEN® (ERIBULIN MESILATE) IN METASTATIC BREAST CANCER

.....

HALAVEN® monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease (see CLINICAL STUDIES). Prior therapy should have included an anthracycline and a taxane unless patients were not suitable for these treatments.

HALAVEN® is indicated as monotherapy for the treatment of locally advanced or metastatic HER2 negative breast cancer after failure of one chemotherapeutic regimen for advanced disease. Patients should have received an anthracycline and a taxane unless these treatments were not suitable.

HALAVEN® – THE ONLY SINGLE-AGENT CHEMOTHERAPY TO SIGNIFICANTLY
EXTEND OVERALL SURVIVAL IN A PHASE III TRIAL IN PATIENTS WITH METASTATIC
BREAST CANCER AFTER PRIOR ANTHRACYCLINE AND TAXANE¹